Articles published by Scribe Therapeutics Inc.

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

September 02, 2026

From Scribe Therapeutics Inc.

Via GlobeNewswire

Tickers SCTX

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 01, 2026

From Scribe Therapeutics Inc.

Via GlobeNewswire

Tickers SCTX

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

July 27, 2026

From Scribe Therapeutics Inc.

Via GlobeNewswire

Tickers SCTX

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

July 23, 2026

From Scribe Therapeutics Inc.

Via GlobeNewswire

Scribe Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 15, 2025

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences

September 09, 2025

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting

May 22, 2025

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly’s Gene Therapy Division

May 05, 2025

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress

April 23, 2025

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference

March 07, 2025

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics to Participate in Upcoming Conferences

February 26, 2025

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi

January 13, 2025

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 09, 2025

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024

October 30, 2024

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics to Participate in Upcoming Conferences

September 12, 2024

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics Presents Data Demonstrating Highly Potent Gene Editing In Vivo, Including Saturated Editing of Hepatocytes in NHPs, by an Engineered XE Genome Editor; Showcases Novel Epigenetic Editing Capabilities at 2024 ASGCT Annual Meeting

May 10, 2024

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

April 22, 2024

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

March 06, 2024

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target

January 03, 2024

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology

December 20, 2023

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases

July 17, 2023

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 19, 2023

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases

May 16, 2023

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 02, 2023

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

March 31, 2023

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics to Participate in Four Upcoming Conferences

November 17, 2022

From Scribe Therapeutics Inc.

Via Business Wire

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 29, 2022

From Scribe Therapeutics Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.